KURA
Kura Oncology, Inc. NASDAQ Listed Sep 16, 2015$9.32
Mkt Cap $827.3M
52w Low $5.45
55.0% of range
52w High $12.49
50d MA $8.79
200d MA $8.96
P/E (TTM)
-2.8x
EV/EBITDA
-2.6x
P/B
4.4x
Debt/Equity
0.1x
ROE
-160.0%
P/FCF
-12.9x
RSI (14)
—
ATR (14)
—
Beta
0.24
50d MA
$8.79
200d MA
$8.96
Avg Volume
1.5M
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
12730 High Bluff Drive · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.72 | -0.92 | -27.8% | 8.51 | -2.7% | +5.3% | +10.3% | +8.8% | +8.3% | +3.9% | — |
| Nov 4, 2025 | AMC | -0.57 | -0.85 | -49.1% | 9.96 | +0.1% | -0.2% | +2.0% | -1.0% | +3.6% | +7.3% | — |
| Aug 7, 2025 | AMC | 0.15 | -0.75 | -600.0% | 5.96 | -4.4% | -7.0% | -7.0% | +4.0% | +8.9% | +10.7% | — |
| May 1, 2025 | AMC | -0.51 | -0.66 | -29.4% | 6.49 | -4.0% | -0.3% | +3.5% | -10.8% | -12.9% | -7.6% | — |
| Feb 26, 2025 | AMC | -0.65 | -0.22 | +66.2% | 7.77 | +2.6% | -1.5% | -0.8% | -6.7% | -5.7% | -5.1% | — |
| Nov 7, 2024 | AMC | -0.64 | -0.63 | +1.6% | 17.77 | -5.6% | -0.5% | -1.2% | +4.5% | -0.1% | -7.2% | — |
| Aug 8, 2024 | AMC | -0.63 | -0.59 | +6.3% | 19.12 | +0.4% | -0.8% | -0.7% | -0.5% | -0.4% | +1.7% | — |
| May 2, 2024 | AMC | -0.56 | -0.59 | -5.4% | 20.59 | -0.2% | +0.2% | +2.0% | +2.3% | -0.2% | +0.9% | — |
| Feb 27, 2024 | AMC | -0.56 | -0.55 | +1.8% | 21.76 | -0.0% | -1.7% | -3.1% | -0.8% | -2.1% | -3.3% | — |
| Nov 2, 2023 | AMC | -0.56 | -0.50 | +10.7% | 8.42 | +4.0% | +7.0% | +6.8% | +10.1% | +7.5% | +2.1% | — |
| Aug 3, 2023 | AMC | -0.57 | -0.53 | +7.0% | 10.54 | -0.5% | +4.4% | -1.0% | -1.3% | +2.1% | +4.7% | — |
| May 10, 2023 | AMC | -0.54 | -0.50 | +7.4% | 11.45 | -0.5% | +8.3% | +6.9% | +10.6% | +9.3% | +8.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | Mizuho | Maintains | Outperform → Outperform | — | $8.32 | $8.23 | -1.1% | -3.0% | +2.8% | +0.5% | -7.0% | -7.1% |
| Mar 13 | UBS | Maintains | Buy → Buy | — | $8.84 | $8.91 | +0.8% | -2.1% | -1.2% | -2.9% | -5.1% | -4.6% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $8.51 | $8.28 | -2.7% | +5.3% | +10.3% | +8.8% | +8.3% | +3.9% |
| Jan 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $9.17 | $9.02 | -1.6% | +0.4% | +2.1% | -2.8% | -7.7% | -6.2% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.17 | $9.02 | -1.6% | +0.4% | +2.1% | -2.8% | -7.7% | -6.2% |
| Nov 24 | Barclays | Maintains | Overweight → Overweight | — | $11.17 | $11.38 | +1.9% | +5.0% | +3.8% | +7.3% | +8.7% | +2.4% |
| Nov 14 | Wedbush | Maintains | Outperform → Outperform | — | $10.68 | $10.75 | +0.7% | +5.0% | +1.6% | +3.7% | +6.0% | +2.8% |
| Nov 14 | UBS | Maintains | Buy → Buy | — | $10.68 | $10.75 | +0.7% | +5.0% | +1.6% | +3.7% | +6.0% | +2.8% |
| Oct 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.84 | $10.24 | +4.1% | +1.5% | -2.6% | -5.7% | -7.5% | -1.4% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.84 | $10.24 | +4.1% | +1.5% | -2.6% | -5.7% | -7.5% | -1.4% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.97 | $8.89 | -0.9% | -1.3% | +2.6% | +1.9% | +6.7% | +9.3% |
| Aug 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.54 | $5.55 | +0.2% | +0.0% | +11.9% | +17.1% | +19.1% | +32.5% |
| Jun 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.80 | $5.80 | +0.0% | -1.2% | -2.2% | -0.5% | -3.4% | +0.2% |
| Jun 20 | Wedbush | Maintains | Outperform → Outperform | — | $6.06 | $6.11 | +0.8% | -3.5% | -3.1% | -1.3% | -4.3% | -5.4% |
| Jun 4 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.42 | $6.46 | +0.6% | +0.5% | +2.3% | +4.8% | +4.8% | +6.1% |
| May 19 | Mizuho | Maintains | Outperform → Outperform | — | $6.02 | $5.96 | -1.0% | +3.7% | +6.0% | +3.0% | +3.7% | -6.3% |
| May 2 | Barclays | Maintains | Overweight → Overweight | — | $6.49 | $6.23 | -4.0% | -0.3% | +3.5% | -10.8% | -12.9% | -7.6% |
| Apr 29 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.51 | $6.51 | +0.0% | +0.2% | +0.8% | -0.3% | -0.6% | +3.2% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.43 | $6.46 | +0.5% | +1.2% | +1.4% | +2.0% | +0.9% | +0.6% |
| Mar 6 | UBS | Maintains | Buy → Buy | — | $7.37 | $7.19 | -2.4% | +4.5% | +2.2% | -1.8% | -0.5% | +4.6% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.77 | $7.97 | +2.6% | -1.5% | -0.8% | -6.7% | -5.7% | -5.1% |
| Feb 6 | Wedbush | Maintains | Outperform → Outperform | — | $9.05 | $8.15 | -9.9% | -2.5% | -4.4% | -2.9% | -7.8% | -7.7% |
| Feb 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.05 | $8.15 | -9.9% | -2.5% | -4.4% | -2.9% | -7.8% | -7.7% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.05 | $8.15 | -9.9% | -2.5% | -4.4% | -2.9% | -7.8% | -7.7% |
| Jan 8 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $8.17 | $8.07 | -1.2% | -4.8% | -10.4% | -11.4% | -11.1% | -11.4% |
| Dec 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.67 | $10.76 | +0.8% | -1.3% | -3.6% | -4.4% | -9.2% | -9.7% |
| Nov 22 | BofA Securities | Maintains | Buy → Buy | — | $10.06 | $10.27 | +2.1% | +7.4% | +8.9% | +6.9% | +11.0% | +9.7% |
| Nov 21 | Jefferies | Maintains | Buy → Buy | — | $15.91 | $11.80 | -25.8% | -36.8% | -32.1% | -31.1% | -32.4% | -29.8% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.91 | $11.80 | -25.8% | -36.8% | -32.1% | -31.1% | -32.4% | -29.8% |
| Nov 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $16.04 | $15.92 | -0.7% | -0.5% | -0.8% | -37.3% | -32.7% | -31.7% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.92 | $15.99 | +0.4% | +0.8% | +0.3% | -0.1% | -36.8% | -32.2% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.57 | $18.63 | +0.3% | -4.4% | -11.2% | -14.3% | -13.6% | -14.1% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.52 | $18.04 | +3.0% | +1.8% | +1.4% | +0.9% | +0.2% | +6.0% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.02 | $17.85 | +4.9% | +4.5% | +2.9% | +4.2% | +2.0% | -0.3% |
| Oct 14 | Stifel | Downgrade | Buy → Hold | — | $18.58 | $17.98 | -3.2% | -2.8% | -2.0% | -1.7% | -2.6% | -3.1% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.97 | $19.09 | +0.6% | +0.1% | +0.3% | +0.4% | +2.5% | +1.5% |
| Aug 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $18.97 | $19.09 | +0.6% | +0.1% | +0.3% | +0.4% | +2.5% | +1.5% |
| Aug 9 | Wedbush | Maintains | Outperform → Outperform | — | $19.12 | $19.20 | +0.4% | -0.8% | -0.7% | -0.5% | -0.4% | +1.7% |
| Aug 9 | Stifel | Maintains | Buy → Buy | — | $19.12 | $19.20 | +0.4% | -0.8% | -0.7% | -0.5% | -0.4% | +1.7% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.94 | $21.15 | +1.0% | +0.7% | -2.1% | -1.6% | -2.1% | -1.7% |
| Jun 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $20.69 | $20.73 | +0.2% | -4.4% | -1.8% | +1.2% | +1.9% | -1.0% |
| May 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $21.87 | $21.78 | -0.4% | +5.1% | +1.4% | +1.7% | +1.1% | +3.1% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.61 | $20.92 | +1.5% | +1.5% | +6.1% | +11.5% | +7.6% | +7.9% |
| May 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $20.63 | $20.77 | +0.7% | +1.8% | +2.1% | -0.4% | +0.7% | +0.4% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.59 | $20.55 | -0.2% | +0.2% | +2.0% | +2.3% | -0.2% | +0.9% |
| May 3 | Wedbush | Maintains | Outperform → Outperform | — | $20.59 | $20.55 | -0.2% | +0.2% | +2.0% | +2.3% | -0.2% | +0.9% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.53 | $18.33 | +4.6% | +3.8% | +6.8% | +7.0% | +8.4% | +12.1% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.04 | $21.31 | +1.3% | +7.9% | +5.8% | +11.8% | +8.5% | +6.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.76 | $21.75 | -0.0% | -1.7% | -3.1% | -0.8% | -2.1% | -3.3% |
| Feb 28 | Wedbush | Maintains | Outperform → Outperform | — | $21.76 | $21.75 | -0.0% | -1.7% | -3.1% | -0.8% | -2.1% | -3.3% |
No insider trades available.
Data updated apr 25, 2026 6:11pm
· Source: massive.com